These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

857 related items for PubMed ID: 19729087

  • 1. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C, Shi H, Zhou J, Liang Y, Xu H.
    Vaccine; 2009 Nov 05; 27(47):6558-63. PubMed ID: 19729087
    [Abstract] [Full Text] [Related]

  • 2. Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV).
    Li Z, Ding W, Guo Q, Liu Z, Zhu Z, Song S, Li W, Liao G.
    Hum Vaccin Immunother; 2018 Nov 05; 14(8):1987-1994. PubMed ID: 29601259
    [Abstract] [Full Text] [Related]

  • 3. Anomalous observations on IPV and OPV vaccination.
    John TJ.
    Dev Biol (Basel); 2001 Nov 05; 105():197-208. PubMed ID: 11763328
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.
    Verdijk P, Rots NY, Bakker WA.
    Expert Rev Vaccines; 2011 May 05; 10(5):635-44. PubMed ID: 21604984
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
    Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A, Kersten GF, van den Heuvel N, Hendriks JT, van der Pol LA.
    Vaccine; 2011 Sep 22; 29(41):7188-96. PubMed ID: 21651934
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
    Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WA.
    Vaccine; 2013 Nov 12; 31(47):5531-6. PubMed ID: 24063976
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Strengths and weaknesses of current polio vaccines--a view from industry.
    André FE.
    Dev Biol (Basel); 2001 Nov 12; 105():61-6. PubMed ID: 11763338
    [Abstract] [Full Text] [Related]

  • 16. [Enhancing the immunogenicity of inactivated polio vaccines with chitosan used as an adjuvant].
    Gendon IuZ, Markushin SG, Akopova II, Krivtsov GG, Akhmatova NK, Koptiaeva IB, Vasil'ev IuM.
    Vopr Virusol; 2011 Nov 12; 56(6):28-32. PubMed ID: 22359946
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion.
    Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MA.
    J Infect Dis; 2005 Mar 15; 191(6):990-9. PubMed ID: 15717277
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.